Asthma Navigator for Childhood Asthma

Overseen By Anne Fitzpatrick, PhD, APRN

Age: < 18

Sex: Any

Trial Phase: Academic

Sponsor: Emory University

Disqualifiers: Cystic fibrosis, Immune deficiency, Prematurity, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 52 weeks

75 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this study is to improve health equity in children aged 5-16.9 years admitted to the PICU for asthma. The objectives are: * To identify the factors related to differential experiences of asthma self-management * To pilot the effectiveness of an individualized asthma navigator intervention at PICU discharge.

Research Team

Anne Fitzpatrick, PhD, APRN

Principal Investigator

Emory University

Eligibility Criteria

This trial is for children aged 5 to nearly 17 who have been admitted to the Pediatric Intensive Care Unit (PICU) due to asthma. It's designed to help improve how they manage their asthma after leaving the PICU.

Inclusion Criteria

I am admitted to the Pediatric Intensive Care Unit for asthma.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the Asthma Navigator intervention, with weekly EMR screenings for asthma exacerbations

52 weeks

Weekly EMR screenings

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Asthma Navigator

Trial Overview The study tests an 'asthma navigator'—a personalized guide or support system—to see if it can help these kids better handle their asthma once they're discharged from the PICU.

Participant Groups

Group I: The Asthma Navigator Experimental Treatment 1 Intervention

The Children's electronic medical record (EMR) of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end.

Group II: Standard of Care Active Control 1 Intervention

This arm will not have access to the Asthma Navigator. The Children's EMR of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end.

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials

1,735

Recruited

2,605,000+

Georgia Clinical & Translational Science Alliance (CTSA)

Collaborator

Trials

2

Recruited

150+